69342-47-8

Basic information

• Product Name: 4-N-BUTYLPHENYL ISOCYANATE
• Synonyms: 4-BUTYLPHENYL ISOCYANATE;P-BUTYLPHENYL ISOCYANATE;Benzene, 1-butyl-4-isocyanato- (9CI);1-Butyl-4-isocyanatobenzene;Isocyanic Acid 4-Butylphenyl Ester;483400_ALDRICH;ZINC02170350;4-N-BUTYLPHENYL ISOCYANATE
• CAS NO: 69342-47-8
• Molecular Formula: C₁₁H₁₃NO
• Molecular Weight: 175.23
• Product Categories: ISOCYANATE;Isocyanates;Nitrogen Compounds;Organic Building Blocks
• Mol File: 69342-47-8.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 108 °C3 mm Hg(lit.)
• Flash Point: 227 °F
• Appearance: /
• Density: 0.992 g/mL at 25 °C(lit.)
• Vapor Pressure: 0.0268mmHg at 25°C
• Refractive Index: n20/D 1.517(lit.)
• Sensitive: Moisture Sensitive
• BRN: 390859
• CAS DataBase Reference: 4-N-BUTYLPHENYL ISOCYANATE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-N-BUTYLPHENYL ISOCYANATE(69342-47-8)
• EPA Substance Registry System: 4-N-BUTYLPHENYL ISOCYANATE(69342-47-8)

Safety Data

• Hazard Codes: Xn,Xi
• Statements: 20/21/22-36/37/38
• Safety Statements: 23-26-36
• RIDADR: UN 2206 6.1/PG 3
• WGK Germany: 3
• HazardClass: 6.1
• PackingGroup: III
• Hazardous Substances Data: 69342-47-8(Hazardous Substances Data)

Usage

General Description

4-N-butylphenyl isocyanate is a chemical compound with the molecular formula C11H13NO. It is a clear liquid with a pungent odor and is used primarily in the production of polyurethane foams and coatings. Exposure to 4-N-butylphenyl isocyanate can cause irritation to the skin, eyes, and respiratory system, and can also lead to sensitization and allergic reactions in some individuals. It is important to handle this chemical with care and to use appropriate protective equipment when working with it. Additionally, proper ventilation and engineering controls should be in place to minimize exposure to 4-N-butylphenyl isocyanate in the workplace.

InChI:InChI=1/C11H13NO/c1-2-3-4-10-5-7-11(8-6-10)12-9-13/h5-8H,2-4H2,1H3

Upstream product

• 104-13-2 4-Butylaniline 
• 32315-10-9 bis(trichloromethyl) carbonate 
• 13478-63-2 p-butylaniline hydrochloride 
• 530-62-1 1,1'-carbonyldiimidazole 

Downstream Products

• 86781-18-2 1,1-Dibutyl-3-(4-butyl-phenyl)-urea 
• 86764-31-0 1,1-Dibenzyl-3-(4-butyl-phenyl)-urea 
• 934198-62-6 tris{3-[N'-(4-n-butylphenyl)ureido]benzyl}amine 
• 220843-56-1 1-(4-n-Butylphenyl)-3-quinolin-4ylurea 
• 897343-09-8 2-isonicotinoyl-N-(4-butylphenyl)hydrazinecarboxamide 
• 57229-08-0 1.3-bis(4-(n-butyl)phenyl)urea 
• 1055717-95-7 C₃₃H₄₉N₃O₃ 
• 693788-58-8 bis(2-nitrobenzyl){2-[N'-(4-butylphenyl)ureido]benzyl}amine 

Relevant articles and documents

Phenylquinoline transient receptor potential vanilloid 1 antagonists for the treatment of pain: Discovery of 1-(2-phenylquinoline-4-carbonyl)-N-(4-(trifluoromethyl)phenyl)pyrrolidine-3-carboxamide

Reported herein is the design, synthesis, and pharmacologic characterization of a class of TRPV1 antagonists constructed on a phenylquinoline platform that evolved from Cinchophen lead. This design composes three sections: a phenylquinoline headgroup attached to an aliphatic carboxamides, which is tethered at a phenyl tail group. Optimization of this design led to the identification of 37, comprising a pyrrolidine linker and a trifluoromethyl–phenyl tail. In the TRPV1 functional assay, using cells expressed hTRPV1, 37 antagonized capsaicin-induced Ca2+ influx, with an IC50 value of 10.2 nM. In the complete mice analgesic model, 37 exhibited better antinociceptive activity than the positive control BCTC in diverse pain models. All of these results suggested that 37 could be considered as a lead candidate for the further development of antinociceptive drugs.

New β-alanine derivatives are orally available glucagon receptor antagonists

A weak human glucagon receptor antagonist with an IC50 of 7 μM was initially found by screening of libraries originally targeted to mimic the binding of the glucagon-like peptide (GLP-1) hormone to its receptor. Optimization of this hit for binding affinity for the glucagon receptor led to ligands with affinity in the nanomolar range. In addition to receptor binding, optimization efforts were made to stabilize the molecules against fast metabolic turnover. A potent antagonist of the human human glucagon receptor was obtained that had 17% oral availability in rats with a plasma half-life of 90 min. The major metabolites of this lead were identified and used to further optimize this series with respect to pharmacokinetic properties. This final optimization led to a potent glucagon antagonist that was orally available in rats and dogs and was efficacious in lowering blood glucose levels in a diabetic animal model.

Synthesis of isocyanates from nitroalkanes

A process for the preparation of aromatic isocyanates from nitroalkanes. A nitromethyl aromatic compound of the general formula: STR1 wherein R and R1 represent hydrogen, halogen, a C1 -C5 alkyl radical, a C1 -C4 alkoxy radical, nitro, isocyanato, an alkoxycarbonylamino, or nitromethyl radical, with R and R1 being the same or different, is heated in the presence of an effective amount of a Lewis acid or Bronsted acid substance to effect a dehydrogenation-isomerization reaction to yield an aromatic isocyanate of the general formula: STR2 The product of the reaction may be recovered as the aromatic isocyanate or the alcohol adduct, a carbamate.